Know Cancer

forgot password

Imaging of the Prostate Gland Using High Field Strength 3T MRI

Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Imaging of the Prostate Gland Using High Field Strength 3T MRI


I. To assess the impact of prostate MRI, without an endorectal coil, done at 3-Tesla on
surgical management. This would be performed by examining the agreement of lesion location
based on the MRI compared to the lesion location based on pathology and/or surgery and local
extent of the disease, i.e. involvement of contiguous organs and local lymph nodes, based on
the MRI compared to the local extent based on pathology and/or surgery.

II. To test the reproducibility of functional MRI (dynamic-contrast enhanced [DCE_MRI] MRI,
magnetic resonance [MR] spectroscopy and diffusion-weighted MRI).


I. To assess the usefulness of MRI data in treatment planning for radiation therapy, and to
test the feasibility of amide-proton-transfer MRI in prostate cancer detection.

II. To evaluate MRI changes in prostate and tumor morphology between endorectal coil versus
no endorectal coil.

III. To assess the usefulness of ex-vivo prostate specimen MRI for accurate co-registration
between in-vivo MRI of the prostate and pathology slides.


Patients undergo 3-tesla (3T) MRI, including DCE-MRI, diffusion-weighted MRI,
amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T
MRI scan at least 24 hours after the initial scan.

Inclusion Criteria:

- Patients with known or suspected prostate disease based on clinical data will be
included in the study; patients with intermediate to high grade prostate cancer
(Gleason's score >= 7 and prostate-specific antigen [PSA] of > 10ng/dl) will be
referred from the outpatient clinics after evaluation by the treating physicians

- Written informed consent will be signed by the patients before the MRI based on the
guidelines approved by the Ohio State University Institutional Review board

- Patients must have an estimated glomerular filtration rate of >= 30 mL/min/1.73m^2
within six weeks of the MRI to be included in the study

Exclusion Criteria:

- Patients with any type of bioimplant activated by mechanical, electronic, or magnetic
means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators,
electronic infusion pumps, etc.)

- Patients with any type of ferromagnetic bioimplant that could potentially be
displaced or damaged

- Patients that have vascular or aneurysm clips, or metallic staples from a surgical

- Patients with permanent tattoo eye liner (may contain metallic coloring)

- Patients that may have shrapnel imbedded in their bodies, such as from war wounds,
metal workers and machinists (metallic fragments in or near eyes), severe auto
accident victims

- Patients that exhibit noticeable anxiety and/or claustrophobia

- Patients who cannot adhere to the experimental protocols for any reason, or have an
inability to communicate with the researcher

- Patients who have cardiac or known circulatory impairment, and/or the inability to
perspire (poor thermoregulatory function)

- Patients with an estimated glomerular filtration rate of < 30 mL/min/1.73m^2 within
six weeks of the MRI

- Acute or chronic severe renal insufficiency (estimated glomerular filtration rate <
30 mL/min/1.73m^2)

- Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative
liver transplantation period

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Diagnostic imaging quality of the prostate at 3T high field imaging without an endorectal coil

Outcome Time Frame:

Up to 6 years

Safety Issue:


Principal Investigator

Michael Knopp, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ohio State University


United States: Institutional Review Board

Study ID:




Start Date:

September 2007

Completion Date:

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms



The Ohio State University Medical Center, StressColumbus, Ohio  43210